ADAM22 and infantile-onset epilepsy: We report 19 additional cases with potentially deleterious variants in ADAM22 identified through next-generation sequencing, of whom 18 had clinical data available, and include additional features of two previously reported cases.25,26 All affected individuals presented moderate-profound global developmental delay, intellectual disability, and infantile-onset epilepsy.